EU risk-sharing agreements between 2000-2015

Category: Abstracted Scientific Content
Visits: 171 total, 3 today

The ageing population, longer life expectancies, and the increasing cost of drugs are expected to significantly increase the burden on healthcare systems in the coming years. To reduce this and increase access to new, innovative and effective drugs in the European Union (EU), risk-sharing agreements (RSAs) between national healthcare payers, health technology assessment (HTA) agencies and the pharmaceutical industry, have been put in place. A recent study published in PharmacoEconomics [1], explores RSAs in the EU from 2000-2015. It shows that there has been increased interest in and uptake of RSAs during this period and discusses the reasons for this increase.

Subscribe now to GaBI Journal to view full information of this article to be published in the next journal issue.

Go Back Print

Leave a Reply